All articles
Does Wegovy® Cause Constipation: Explanation & Expert Tips
Reading time:
6 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
How Wegovy's Constipation Risk Compares to Other Medications
Regarding weight loss medications, side effects are inevitable, but they vary depending on the medication's mechanism. Let's compare how constipation rates compare among different options (7,8,9,10)
Wegovy® vs. Other GLP-1 Agonists: As part of the GLP-1 receptor agonist family, Wegovy® shares side effect profiles similar to those of its counterparts. However, due to its unique formulation and dosing schedule, individual experiences may vary.
Zepbound® or Mounjaro® (Tirzepatide): 6% to 17% constipation
Victoza (Liraglutide): 19% constipation
Wegovy® (Semaglutide): 3% to 24% constipation
Wegovy® vs. Traditional Weight Loss Drugs: Compared to older weight loss medications, GLP-1 agonists like Wegovy® typically offer a more favorable side effect profile, including fewer cardiovascular risks and different gastrointestinal effects.
Bupropion: 8% to 26% constipation
Topiramate: 1% to 4% constipation
Orlistat: While constipation isn't a side effect, up to 5% may experience diarrhea instead.
Key Takeaways: Managing Your Wegovy® Treatment
Whether you're using Wegovy® or another weight loss medication, constipation can be frustrating. However, managing this common side effect is possible with the right strategies. Dietary adjustments, lifestyle changes, and possibly medical interventions can prevent and alleviate constipation discomfort. Remember to speak with your doctor about the benefits and potential side effects of any medication carefully.
With proactive steps and guidance from obesity medicine experts, individuals on Wegovy® can minimize discomfort and maximize their weight loss journey. The weight care program at Mochi Health offers 1-on-1 visits with providers who can provide a personalized plan for you. They’ll help you find the right medication choice and dosage to provide lasting results while mitigating common side effects. See if you’re eligible for the weight loss program today and get access to virtual care and medications delivered right to your door.
References:
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism (Germany), 46, 101102–101102. https://doi.org/10.1016/j.molmet.2020.101102
Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. Am J Gastroenterol 2023; 118:936.
Erdogan, A., Rao, S. S. C., Thiruvaiyaru, D., Lee, Y. Y., Coss Adame, E., Valestin, J., & O’Banion, M. (2016). Randomised clinical trial: mixed soluble/insoluble fibre vs. psyllium for chronic constipation. Alimentary Pharmacology & Therapeutics, 44(1), 35–44. https://doi.org/10.1111/apt.13647
Tantawy, S. A., Kamel, D. M., Abdelbasset, W. K., & Elgohary, H. M. (2017). Effects of a proposed physical activity and diet control to manage constipation in middle-aged obese women. Diabetes, Metabolic Syndrome and Obesity, 10, 513–519. https://doi.org/10.2147/DMSO.S140250
Arnaud, M. J. (2003). Mild dehydration: a risk factor of constipation? European Journal of Clinical Nutrition, 57(S2), S88–S95. https://doi.org/10.1038/sj.ejcn.1601907
Bellini, M., Tonarelli, S., Barracca, F., Rettura, F., Pancetti, A., Ceccarelli, L., Ricchiuti, A., Costa, F., de Bortoli, N., Marchi, S., & Rossi, A. (2021). Chronic Constipation: Is a Nutritional Approach Reasonable? Nutrients, 13(10), 3386-. https://doi.org/10.3390/nu13103386
Sun, F., Chai, S., Yu, K., Quan, X., Yang, Z., Wu, S., Zhang, Y., Ji, L., Wang, J., & Shi, L. (2015). Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technology & Therapeutics, 17(1), 35–42. https://doi.org/10.1089/dia.2014.0188
Jastreboff, A. M., Aronne, L. J., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. Reply. The New England Journal of Medicine, 387(15), 1434–1435. https://doi.org/10.1056/NEJMc2211120
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet (British Edition), 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. The Lancet (British Edition), 377(9774), 1341–1352. https://doi.org/10.1016/S0140-6736(11)60205-5
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles















